【摘要】 目的研究DROSHA rs10719 T>C与胃癌临床病理特征及预后的关系。方法 97例接受奥沙利铂联合氟尿嘧啶类药物术后辅助化疗的Ⅰ~Ⅲ期胃癌患者,分析rs10719遗传变异与胃癌临床病理特征及预后的相关性。结果全组患者2年DFS为60.8%,3年OS为73.8%。显性模型与淋巴结转移相关,TC+CC基因型患者淋巴结转移发生率低于TT基因型(P=0.031)。显性模型与临床分期显著相关,TT基因型中Ⅲ期患者明显多于TC+CC基因型(P=0.021)。有、无淋巴结转移患者3年OS分别为89.3%和63.3%(P=0.013),Ⅰ、Ⅱ、Ⅲ期患者3年OS分别为100.0%、88.6%和55.8%(P=0.015),具有显著统计学差异。rs10719遗传变异与患者生存无明显相关性。多因素预后分析显示,淋巴结状态(P=0.014,RR:9.556,95%CI:1.586~57.590)为独立预后因素。结论 DROSHA rs10719 T>C遗传变异可能与胃癌患者淋巴结转移状态及临床分期相关。更多还原

【Abstract】 Objective To investigate the association between DROSHA rs10719 T>C and clinicopathologic characteristics and prognosis of gastric cancer patients.Methods 97 patients with stage Ⅰ~Ⅲgastric cancer treated with radical gastrectomy and adjuvant chemotherapy of oxaliplatin and fluorouracils were analyzed.Correlation between DROSHA rs10719 T>C and clinicopathologic characteristics and prognosis of gastric cancer patients were analyzed.Results 2-year DFS rate was 60.8% and3-year OS rate was 73.8%.In dominant model,we found that rs10719 TC+CC genotype carriers were less likely to develop lymph node metastasis(P=0.031).Compared with TC+CC genotype carriers,more patients with TT genotype were in stage Ⅲ(P=0.021).3-year OS was significantly different between patients with or without lymph node metastasis(89.3% vs 63.3%,P=0.013)and among patients with stage Ⅰ~Ⅲ disease(100.0%,88.6% and 55.8%,P=0.015).rs10719 was not related with survival.Multi-variants’ cox regression analysis showed that lymph node status(P=0.014,RR:9.556,95% CI:1.586 ~57.590)was independent prognostic factor.Conclusion DROSHA rs10719 T>C could be associated with lymph node metastasis and clinical stage of gastric cancer patients.更多还原